KRYS
Krystal Biotech Inc
350.90$
+5.1%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | +2,196.7% | +131.7% | +80.0% | +48.7% | +101.5% | -10.8% | +46.5% | +29.0% | +26.3% | |
| – | +2,201.2% | +125.7% | +73.9% | +40.4% | +60.8% | -13.2% | +53.2% | +26.2% | +38.1% | |
| – | +2,478.8% | +109.1% | +80.9% | +43.1% | +27.2% | -52.6% | +121.3% | -3.8% | +43.9% | |
| – | +2,478.8% | +125.4% | +73.3% | +40.1% | +61.5% | -13.5% | +40.4% | +12.3% | +38.5% | |
| – | – | – | – | – | – | – | – | +149.2% | +21.7% | |
| – | – | – | – | – | – | – | – | +279.5% | +52.7% | |
| – | +1,438.5% | +1,407.0% | +271.1% | +176.1% | +287.3% | +41.9% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | |
| – | -66.2% | +351.6% | +111.4% | +207.1% | +74.4% | +10.7% | +9.6% | +175.6% | +4.4% | |
| – | +1,388.4% | +305.6% | +28.2% | +364.4% | +66.6% | +12.1% | +14.7% | +208.2% | +0.9% | |
| – | – | – | – | +1,616.3% | -87.4% | +50.0% | -5.6% | -17.4% | +45.5% | |
| – | +359.5% | +360.1% | +15.0% | +106.2% | +299.0% | -52.6% | -53.6% | +169.6% | -35.0% | |
| – | -100.0% | – | – | – | – | – | – | – | – | |
| – | +17,019.0% | +128.9% | +79.2% | +43.9% | +103.2% | -12.0% | +49.1% | +21.5% | +28.9% | |
| – | – | – | – | – | – | – | – | – | – | |
| – | +25.4% | +109.0% | +41.9% | +18.2% | +18.1% | +14.8% | +8.9% | +7.2% | +0.7% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.